QR Kod

The immunological fitness of NSCLC patients drives the response to anti-PD1-based immunotherapy regardless of age

Abstract Background Over the past decade, the number of elderly cancer patients has increased, including those with NSCLCs, most of whom are over 60 years old. NSCLC patients receive anti-PD1-based therapies. These therapies directly target the immune system by activating T cells. However, older pat...

Ful tanımlama

Kaydedildi:
Asıl Yazarlar: Lucrezia Tuosto, Alain Gelibter, Lidia Strigari, Angela Asquino, Marco Siringo, Angelica Pace, Flavio Valentino, Davide Capozzi, Serena Bianchini, Filippo Bellati, Daniele Santini, Marianna Nuti, Ilaria Grazia Zizzari, Aurelia Rughetti, Chiara Napoletano
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMC 2026-02-01
Seri Bilgileri:Journal of Translational Medicine
Konular:
Non-small cell lung cancer
Elderly patients
anti-PD1 treatment
Immunotherapy
Online Erişim:https://doi.org/10.1186/s12967-026-07719-9
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller